Esperion's new cholesterol-lowering drug, Bempedoic Acid, achieves positive results in the 5th trial

(October 28), EsperionPharmaceutical
( it said it had achieved positive results in the
of its new, theof cholesterolbempedoic acid only needs to be taken by oral once dailyresults showed that theof the drug bempedoic acid and the largest dose of statin
s (after 12 weeks of combination therapy, LDL) cholesterol in the patient's body was reduced by 18%Thecompany(plans to submit all data to the U.SFDAin the first few months of 2019the data the release is the last of Esperion's five phase 3 clinical trials of bempedoic acid alone and combination therapy, which performed well in previously published trials and reached the end of the main study if approved, the small biotech company would shake up a market dominated by giant pharmaceutical companies, which Esperion Pharmaceuticals believes can achieve lower cholesterol levels in patients at a lower price than other drugs bempedoic acid
Bempedoic acid is a world-first (first-in-class) complementary, daily oral ATP citric acid lysate inhibitor that lowers cholesterol by raising LDL receptors to synthetic (and LDL-C) similar to statins, bempedoic acid also reduces hypersensitivity C-reactive protein (hsCRP) However, there may be some problems with the safety of the drug Deaths occurred in 779 patient studies, but it was not possible to tell whether it was caused by drugs or other causes Although the difference between the placebo group and the treatment group was not sufficient to rule out random opportunities, and none of the causes of death were attributed to the drug, it was enough to raise concerns